Skip to main content
. 2020 Jul 21;1(4):100055. doi: 10.1016/j.xcrm.2020.100055

Figure 4.

Figure 4

Non-CF Subjects with PsA Have Decreased α Diversity and Greater Prevalence of Non-mucoid PsA, Which Was Associated with an Increased Risk of CLAD or Death

(A) Shannon and Simpson α diversity metrics for transplant recipients stratified by CF and PsA culture status (CF−PsA− n = 9, CF+PsA− n = 6, CF−PsA+ n = 6, CF+PsA+ n = 9; Wilcoxon rank-sum; ∗p ≤ 0.05 and ∗∗p < 0.01).

(B) PsA abundance measured by qPCR and compared to culture status for CF and non-CF lung transplant recipients (Wilcoxon rank-sum; ∗p ≤ 0.05).

(C) Comparison of mucoid or non-mucoid PsA strains cultured from CF and non-CF transplant recipients (n = 119 PsA+ cultures, generalized estimating equations (GEE)-adjusted linear model, p = 0.01).

(D) Age-adjusted Cox proportional HR and 95% CI for CLAD or death based upon CF and mucoid PsA strata for increasing number of positive PsA cultures. HR = 1 (solid gray line).